statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market cap on Thursday after the companies announced their decision to terminate the development of their...

Ionis, Biogen Down on Ending Development of ALS Drug

Joe Raedle / Staff / Getty Images

 Key TakeawaysThe Dow, S&P 500, and Nasdaq rose to fresh highs on Thursday, May 16, 2024, amid enthusiasm for corporate earnings and optimism about Federal...

Top Stock Movers Now: Walmart, Canada Goose, Deere, and More

Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.
read more...

Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in...

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track...

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Latest Ratings for BIIB
 DateFirmActionFromTo Mar 2022StifelDowngradesBuyHold Mar 2022RBC CapitalUpgradesSector PerformOutperform Feb 2022Canaccord GenuityMaintainsBuy
 View More Analyst Ratings...

The Analyst Landscape: 27 Takes On Biogen

A new report from Morgan Stanley finds that people using GLP-1 drugs among them Ozempic, Wegovy, Mounjaro, and Zepbound reduce their consumption of tobacco and alcohol while taking the...

Ozempic hits booze sales, Moderna likes AI, and Biogen's blockbuster drug: Pharma news roundup

These Analysts Revise Their Forecasts On Biogen After Q1 Results

Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore

 Hot on the heels of last week's tech and momentum rout, shaken traders will have to wait until Friday for the main...

Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore

Biogen Unusual Options Activity For April 18

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Watchers	18,535
52-Wk Low	$189.44
52-Wk High	$319.76

Volume	985,059.00
52-Wk High	$319.76
52-Wk Low	$189.44

BIIB Biogen Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community